ADA Scientific Sessions 2026 Abstract

Long-Term Safety and Efficacy of HTD1801 in Patients with Type 2 Diabetes: Two Phase 3 Open-Label Extensions

By Yingying Luo, Jianhua Ma, Zhifeng Cheng, Linong Ji

Trial in peopleInterventions

The paper

Yingying Luo, Jianhua Ma, Zhifeng Cheng, Linong Ji

Beijing

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 1823-P

doi.org/10.2337/db26-1823-p

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety